6 Likes
ITP Bombshell: 11 Highly Anticipated Longevity Compounds Fail to Extend Lifespan in Elite Multi-Site Trial
The pursuit of pharmacological lifespan extension just hit a massive reality check. The Interventions Testing Program (ITP), widely considered the gold standard for preclinical longevity research, evaluated eleven promising compounds in its C2022 cohort. The results were unequivocally negative. Conducted across three independent testing sites in the USA (The Jackson Laboratory, University of Michigan, and University of Texas Health Science Center at San Antonio) and published in GeroScience, the study found that none of the interventions significantly increased lifespan in male or female mice.
The impact score of this journal is 4.9, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
The most striking finding is the failure of compounds that previously demonstrated lifespan extension in earlier ITP cohorts. Astaxanthin, meclizine, and mitoglitazone—all former standouts in the longevity community—showed zero benefit when administered at different doses or initiated at alternate starting ages. Even more concerning, several metabolic modulators actively accelerated mortality in females. Astaxanthin, late-start mitoglitazone, and pioglitazone were associated with significantly reduced lifespans in the pooled female cohorts.
This study underscores a brutal truth in aging biology: biological context is paramount. Efficacy is highly constrained by narrow therapeutic windows, precise dosing requirements, and rigid temporal initiation points. A drug that extends lifespan when given at 12 months might be useless or harmful if started at 7 or 16 months. Furthermore, an unexplained statistical anomaly at The Jackson Laboratory resulted in unusually long-lived control females, forcing researchers to reanalyze the data without that site. Even with this correction, mitoglitazone and pioglitazone remained actively toxic to female longevity.
This is a sobering moment for longevity therapeutics. It emphasizes the absolute necessity of rigorous, multi-site replication and exposes the severe limitations of single-cohort findings.
Technical Biohacker Analysis
Study Design Specifications
- Type: In vivo.
- Subjects: Mus musculus (UM-HET3 genetically heterogeneous mice).
- Sex: Male and Female.
- N-Number (Males): Control n=300. Treatment groups n=150–210.
- N-Number (Females): Control n=272 (pooled). Control n=180 (excluding TJL). Treatment groups n=130–132 (pooled). Treatment groups n=86–88 (excluding TJL).
Lifespan Analysis & Reference Context
Evaluating baseline control lifespans is critical for interpreting negative data. Pabis et al. (2023) established a “900-day rule,” stipulating that robust lifespan extension claims require control cohorts to live approximately 900 days, as short-lived controls can artificially inflate intervention efficacy.
- Male Controls: The pooled male controls achieved a median lifespan of 813 days. This falls short of the 900-day metric, indicating these males were short-lived. Despite this lower baseline, no intervention provided a survival advantage.
- Female Controls: The pooled female controls reached a median of 903 days. However, this was artificially inflated by the TJL site, where control females lived an unusually long time (Z=3.13, p=0.0017). Excluding TJL, the UM and UT control females had a median lifespan of 855 days, which also sits below the optimal 900-day threshold.
Lifespan Data
- Males: Median lifespan changes ranged from -1.66% (Meclizine late-start) to +9.23% (Meclizine high-dose), none of which reached statistical significance. Maximum lifespan (p90) changes ranged from -4.07% to +2.53% (non-significant).
- Females (Excluding TJL anomaly): Pioglitazone caused a significant median lifespan decrease of -6.20% (p=0.004). Late-start M160 also decreased median lifespan by -0.70% (p=0.034). Late-start M160 reduced maximum lifespan (p90) by -6.45% (p=0.015).
Mechanistic Deep Dive
- mTOR & AMPK Pathways: Meclizine is an mTORC1 inhibitor. It previously showed an 8% median lifespan increase in males when started at 12 months (800 ppm). Hypothesizing that late-life mTOR inhibition might mirror Rapamycin’s success, researchers tested late-start (16 months) and high-dose (1727 ppm) meclizine. Both parameters failed to alter lifespan.
- Mitochondrial Dynamics & PPARÎł: Mitoglitazone (M160) and pioglitazone are PPARÎł-mediated insulin sensitizers. M160 previously extended male lifespan by 9% when started at 7 months. Initiating M160 at 18 months showed zero benefit for males. In females, both compounds actively suppressed longevity.
- Organ-Specific Priorities (Metabolic): The metabolic interventions provoked severe sex-specific dimorphisms. Pioglitazone and M160 significantly increased body weight in males at 12, 18, and 24 months. Conversely, females on pioglitazone did not differ in weight from controls. Females on pioglitazone suffered significant lifespan reductions.
- Autophagy/Antioxidant Pathways: Astaxanthin is an Nrf2 activator and mitochondrial antioxidant. It previously extended male lifespan by 12% (4000 ppm at 12 months). Lowering the dose (880 ppm) or altering the start time (7 or 16 months) eliminated all longevity benefits in both sexes.
Novelty
This paper shatters the assumption that previously validated longevity interventions possess broad, robust therapeutic windows. It explicitly demonstrates that minor modifications to drug concentration or chronological initiation points can entirely negate life-extending properties.
Critical Limitations
- Translational Uncertainty: The extreme sensitivity to dosing and timing makes extrapolation to human clinical protocols highly speculative. Identifying the exact analogous human intervention window for these compounds remains unsolved. [Confidence: High]
- Methodological Weaknesses: The study suffered a massive statistical anomaly with the TJL control females. These animals lived inexplicably longer than 17 previous historical cohorts sharing the exact same room, water, bedding, and diet. This unknown confounding variable necessitated complex post-hoc data exclusion to salvage the female analysis.
- Effect-Size Uncertainty: The authors make a devastating admission regarding the prior positive results for Astaxanthin, Meclizine, and M160. These previous results were hovering near the statistical lower limit for 80% detection power. Because p-values were nominal, the authors note that these prior “hits” might have simply been statistical chance. [Confidence: High]
- Missing Data: The paper lacks physiological and molecular pathology at the time of death. Without necropsy data or molecular biomarker profiling, we cannot determine why the PPARÎł modulators killed the female mice prematurely, nor why the previously successful pathways failed to engage. [Confidence: High]
More Granular Details:
Male Cohort Results
No compounds yielded a statistically significant median or maximum lifespan extension in males.
- Novel Interventions: Mifepristone, Atorvastatin-telmisartan (Atortel), Methotrexate, and Pioglitazone failed to extend lifespan.
- Altered Protocols of Prior “Hits”: Compounds that previously showed lifespan benefits in the ITP failed to replicate success when administered at different doses or starting ages. These included Alpha-ketoglutarate (7-month start), Astaxanthin (880 ppm at 11 or 16 months), Mitoglitazone (18-month start), and Meclizine (16-month start at 68 ppm or 1727 ppm)
Female Cohort Results
No interventions increased female lifespan. Furthermore, several interventions actively accelerated mortality.
-
Lifespan Reduction (Pooled Data): When data from all three testing sites were pooled, Astaxanthin, late-start Mitoglitazone, and Pioglitazone were associated with significantly reduced lifespans.
-
Lifespan Reduction (Corrected Data): The Jackson Laboratory (TJL) site recorded anomalous, unusually long lifespans in their control females, measuring 3.13 standard deviations above the historical mean. Reanalysis excluding the TJL data confirmed that Mitoglitazone and Pioglitazone still exerted a significantly negative impact on female lifespan.
-
Specific Toxicity Metrics (Excluding TJL): Pioglitazone significantly decreased median lifespan by 6.20% (p=0.004). Late-start Mitoglitazone significantly reduced median lifespan by 0.70% (p=0.034) and reduced maximum lifespan (survival to the 90th percentile) by 6.45% (p=0.015)
Compounds Tested and Human Equivalent Dosing Levels:
Here is the translational pharmacological breakdown for each compound evaluated in the ITP C2022 cohort.
Note on calculations: The conversions utilize the standard laboratory mouse metabolic rate assumption (1 ppm in diet = 0.15 mg/kg of body weight) and the FDA body surface area (BSA) normalization formula: Mouse Dose (mg/kg) / 12.33 = Human Equivalent Dose (HED).
1. Alpha-Ketoglutarate (AKG)
-
Human Equivalent Dose (HED): The achieved dose was 3,262 ppm.
3,262 ppm * 0.15 = 489.3 mg/kg.489.3 / 12.33 = 39.7 mg/kg. For a 60 kg adult: ~2,382 mg/day (2.4 grams/day). - Pharmacokinetics (PK/PD): Rapid absorption with extremely low unformulated oral bioavailability (<10%) due to rapid gastrointestinal and hepatic metabolism. Half-life is extremely short (<1 hour).
- Safety & Toxicity: Safety profile is excellent. NOAEL in animal models is extremely high (>5 g/kg). Generally recognized as safe (GRAS) status. No severe liver/kidney signals at standard doses.
- Biomarker Verification: Target engagement is verified via DNA methylation age clocks (e.g., TruAge) and reduction in systemic inflammatory cytokines (IL-6, TNF-alpha), as AKG acts as a cofactor for TET enzymes involved in epigenetic demethylation.
- Feasibility & ROI: Highly feasible. Widely available as an over-the-counter dietary supplement (often bound to Calcium or Ornithine to improve stability). The HED of 2.4g/day is roughly $30–$60/month.
2. Astaxanthin (Asta)
-
Human Equivalent Dose (HED): The achieved dose was 880 ppm.
880 ppm * 0.15 = 132 mg/kg.132 / 12.33 = 10.7 mg/kg. For a 60 kg adult: ~642 mg/day. - Pharmacokinetics (PK/PD): Highly lipophilic. Bioavailability is notoriously poor unless consumed with dietary fats or formulated in lipid-based delivery systems. Half-life is approximately 16 hours.
- Safety & Toxicity: Exceptional safety profile. NOAEL in rats is over 14 g/kg/day. However, long-term human safety data for massive doses (>100 mg/day) remains sparse.
- Biomarker Verification: Target engagement is tracked via reduced plasma malondialdehyde (MDA), reduction in oxidized LDL, and upregulation of Nrf2 downstream targets (e.g., HO-1).
- Feasibility & ROI: Feasibility for this exact protocol is poor due to cost. Standard human supplements contain 4 to 12 mg. Attempting to ingest 642 mg/day would cost upwards of $300–$600/month. The ROI is deeply unfavorable given the negative ITP results.
3. Atorvastatin & Telmisartan (Atortel)
-
Human Equivalent Dose (HED): The achieved dose was 48 ppm (Atorvastatin) and 27 ppm (Telmisartan).
-
Atorvastatin:
48 * 0.15 = 7.2 mg/kg.7.2 / 12.33 = 0.58 mg/kg. 60 kg adult: ~35 mg/day. -
Telmisartan:
27 * 0.15 = 4.05 mg/kg.4.05 / 12.33 = 0.33 mg/kg. 60 kg adult: ~20 mg/day.
-
Atorvastatin:
- Pharmacokinetics (PK/PD): Atorvastatin has low bioavailability (~14%) and a 14-hour half-life. Telmisartan has higher bioavailability (~42%) and a long 24-hour half-life.
- Safety & Toxicity: Both are FDA-approved. Atorvastatin carries risks of hepatotoxicity (liver enzyme elevation) and statin-induced myopathy. It is heavily metabolized by CYP3A4. Telmisartan carries risks of hypotension and hyperkalemia.
- Biomarker Verification: Systemic target engagement is easily verified via standard lipid panels (ApoB and LDL-C reduction), hs-CRP reduction, and continuous blood pressure monitoring.
- Feasibility & ROI: Highly feasible. Both are cheap, generic prescription drugs. Monthly cost is negligible ($10–$20) with a prescription.
4. Mitoglitazone (M160)
-
Human Equivalent Dose (HED): The achieved dose was 126 ppm.
126 * 0.15 = 18.9 mg/kg.18.9 / 12.33 = 1.53 mg/kg. For a 60 kg adult: ~92 mg/day. - Pharmacokinetics (PK/PD): It is a PPARÎł-sparing thiazolidinedione designed to modulate the mitochondrial pyruvate carrier (MPC) without the systemic fat accumulation associated with classical TZDs.
- Safety & Toxicity: Safety Data Absent for widespread human use. Liver toxicity is the historical barrier for the broader TZD class. The fact that it actively shortened the lifespan of female mice in this ITP cohort flags severe preclinical toxicity.
- Biomarker Verification: Target engagement relies on metabolic markers: improved HOMA-IR, reduction in fasting insulin, and mitochondrial functional assays (specifically MPC flux).
- Feasibility & ROI: Not feasible. M160 is a research chemical unapproved for human medical use.
5. Meclizine (Mec)
-
Human Equivalent Dose (HED): Evaluated at two achieved doses: 68 ppm and 1,727 ppm.
-
Late/Low Dose (68 ppm):
68 * 0.15 = 10.2 mg/kg.10.2 / 12.33 = 0.82 mg/kg. 60 kg adult: ~50 mg/day. -
High Dose (1,727 ppm):
1727 * 0.15 = 259.05 mg/kg.259.05 / 12.33 = 21.0 mg/kg. 60 kg adult: ~1,260 mg/day.
-
Late/Low Dose (68 ppm):
- Pharmacokinetics (PK/PD): Well absorbed orally, distributed widely, including crossing the blood-brain barrier. Half-life is roughly 6 hours.
- Safety & Toxicity: Standard human doses (25–50 mg) are safe (FDA-approved for vertigo). However, the “High Dose” protocol (1,260 mg/day) pushes into dangerous overdose territory. Massive doses of first-generation antihistamines cause severe anticholinergic toxicity (delirium, tachycardia, coma).
- Biomarker Verification: Assessing longevity engagement requires measuring systemic mTORC1 inhibition, typically verified via reduced phosphorylation of downstream effectors like S6K1 in peripheral blood mononuclear cells (PBMCs).
- Feasibility & ROI: While 50 mg/day is a cheap, easily obtainable over-the-counter protocol ($5/month), the failure of this drug in the ITP combined with the neurotoxic profile of high doses renders it a poor candidate for human longevity biohacking.
6. Methotrexate (Meth)
-
Human Equivalent Dose (HED): The achieved dose was 0.3 ppm.
0.3 * 0.15 = 0.045 mg/kg.0.045 / 12.33 = 0.0036 mg/kg. For a 60 kg adult: ~0.22 mg/day. - Pharmacokinetics (PK/PD): Oral bioavailability is ~60%. Half-life ranges from 3 to 10 hours for low doses.
- Safety & Toxicity: Methotrexate is an intense immunosuppressant and abortifacient with severe black box warnings (hepatotoxicity, bone marrow suppression, pulmonary toxicity). However, the HED calculated here (0.22 mg/day) represents an extreme microdose compared to the standard human clinical doses used for rheumatoid arthritis (7.5 to 25 mg/week).
- Biomarker Verification: Target engagement is confirmed by measuring dihydrofolate reductase (DHFR) inhibition and downstream reductions in systemic inflammatory markers.
- Feasibility & ROI: Requires a prescription. Generic methotrexate is extremely cheap, but prescribing an immunosuppressive chemotherapeutic off-label for “longevity” microdosing is highly improbable in clinical practice.
7. Mifepristone (Mife)
-
Human Equivalent Dose (HED): The achieved dose was 30 ppm.
30 * 0.15 = 4.5 mg/kg.4.5 / 12.33 = 0.36 mg/kg. For a 60 kg adult: ~22 mg/day. - Pharmacokinetics (PK/PD): Rapidly absorbed with an oral bioavailability of ~69%. It has a notably long half-life of roughly 85 hours.
- Safety & Toxicity: It is a major substrate of CYP3A4. At clinical doses, it carries warnings for severe vaginal bleeding, bacterial infections, and potential hepatotoxicity.
- Biomarker Verification: Target engagement requires tracking the blockade of glucocorticoid receptors, typically monitored via massive compensatory spikes in plasma ACTH and cortisol.
- Feasibility & ROI: Zero feasibility. Mifepristone is highly regulated due to its abortifacient properties and requires restrictive Risk Evaluation and Mitigation Strategy (REMS) programs in the USA.
8. Pioglitazone (Pio)
-
Human Equivalent Dose (HED): The achieved dose was 94 ppm.
94 * 0.15 = 14.1 mg/kg.14.1 / 12.33 = 1.14 mg/kg. For a 60 kg adult: ~68 mg/day. - Pharmacokinetics (PK/PD): Rapidly absorbed (bioavailability >80%). The half-life of unchanged pioglitazone is 3-7 hours, but active metabolites persist for 16-24 hours.
- Safety & Toxicity: FDA-approved (Actos), but heavily burdened by black box warnings. It can cause or exacerbate congestive heart failure. There is an ongoing, highly debated risk signal regarding bladder cancer. Metabolized heavily by CYP2C8. In this ITP cohort, pioglitazone actively reduced the lifespan of female mice by 6.2%.
- Biomarker Verification: Clinical engagement is verified via reduced HbA1c, improved fasting glucose, and significant increases in serum adiponectin (a direct marker of PPARÎł activation).
- Feasibility & ROI: It is a cheap, widely available generic prescription drug. However, the human clinical maximum dose is typically capped at 45 mg/day due to edema and heart failure risks. Attempting a 68 mg/day protocol while risking the severe female toxicity observed in the ITP makes this a deeply unfavorable target.
4 Likes
But, on the bright side, it reduces my supplement list. 
8 Likes
I’m not a researcher, so by all means correct me, but this would seem to invalidate a number of conclusions, or at very least imply the good sense of a reassessment of the assertion “exact same room, water, bedding, and diet.”
I’m not a researcher. Then again, I’m also not a female mouse. 
1 Like
This gives me way more questions now than answers
It’s a shame I joined the community so late. I had no idea that regular people could actually submit compounds for testing. I have a long list of niche compounds I wanted to submit to the ITP, all of them have huge potential, unlike things like Telmisartan, which you can already tell won’t make the cut. My very first post was actually out of curiosity about why everyone is so obsessed with Telmisartan; that compound has nothing to do with anti-aging.
Just start writing up ITP submissions and plan to get them in by next February. There is always next year.
1 Like
Testing Atorvastatin and telmisartan in mice and watching them fail doesn’t mean a whole lot translating to humans since mice don’t really die of heart problems
4 Likes
Neither does astaxanthin’s effect on eye and skin health. But I do now consider the NRF2/antioxidant pathway a dead end for longevity/cancer prevention. I bet the GLYNAC 25% lifespan effect seen in the other lab wouldn’t be reproduced in the ITP.
2 Likes
Another theory was that Astaxanthin was supposed to act on the FOX-O pathway
2 Likes
A negative result is still very valuable, just means there’s a much lower probability that that specific intervention is broadly effective in the same failure pathways that humans and mice share. So things like pioglitazone and astaxanthin seem reasonable to focus much less on.
I don’t this changes much with regards to Atorvastatin/Telmisartan’s likely longevity benefits, because mice don’t die from ASCVD, whereas in humans it’s a primary failure mode. It just means ASCVD isn’t cleanly tied to cancer. Even major levels of metabolic dysregulation aren’t enough to cause ASCVD death in regular mice.
3 Likes
It is only these two that I had hope might show positive results (but as you say mice don’t die of heart disease, so in humans might be a different story) because the rest of them I don’t take them and I wouldn’t have thought they’d increase lifespan. I also like @Virilius don’t think GLYNAc has any longevity merit while might yield some health benefit.
According to Grok, the human equivalent dose that was used of Astaxanthin this time was around 750mg or a 70kg person while roughly 3.4g was used in the last one that showed 13% lifespan extension. In other words, they still used a MASSIVE dose, but it was a less massive one.
So I guess a human would need to take like 20 bottles at once every day to see benefit (don’t try this at home though)
1 Like